期刊文献+

胰腺癌螺旋断层调强放疗剂量学分析 被引量:1

To Analyze Dosemitry in Helical Tomotherapy For Pancreas Carcinoma
下载PDF
导出
摘要 目的:分析胰腺癌螺旋断层调强放疗(Helical Tomotherapy,HT)靶区剂量和危及器官受量,给临床医生选择合适的照射剂量提供依据。方法:对13例进行螺旋断层调强放疗的胰腺癌病人靶区剂量分布和危及器官的进行回顾行分析,探讨剂量实施的合理性。结果 95%和100%的处方剂量覆盖的临床靶区(CTV)体积分别平均为99.03%和95.69%,CTV适形指数(CI)和靶区剂量均匀指数(HI)分别平均为0.81±0.10和1.08±0.02。放疗计划中十二指肠的V30、V20、V10分别平均为11.91±6.46℅、32.56±23.14℅、62.49±22.57℅,右肾的V20、V10分别平均为12.09±12.05℅、35.82±2.96℅,左肾的V30、V20和V10分别为2.05±1.80℅、12.79±8.42℅和29.56±16.56℅,脊髓最大受量平均为28.02±2.96 Gy,胃的V30、V20和V10平均受量为10.08±4.93%、20.28±8.51%和35.03±24.11℅。结论:胰腺癌螺旋断层调强放疗在给予靶区根治剂量的同时,能有效地降低危及器官的高剂量区,并把危及器官的照射剂量限制在耐受剂量以下。 objective: To analyze dose of target and organs at risk during the helical tomotherapy (HT)for for pancreas carcino- ma. Methods: The retrospective review enrolled 13 pancreas carcinoma patients treated with HT and had,evaluate target vol- umn dose distribute and spare normal tissue.Results: CTV had good CI, HI, separately was 0.81 ±0.10,1.08±0.02. The V100,V95 of CTV were 95.69±0.03%,99.03±0.05%.The V30,V20 and V10 of duodenum were 11.91±6.46%,32.56±23.14% and 62.49±22.57% .The V30 V20 and V10 of left kidney were 2.05±1.80% , 1 2.79±8.42%and 29.56±16.56%. The V20 and V10 of right kid- ney were 12.09±12.05% and35.82±2.96%.The V30,V20 and V10 of stomach were 10.08 ±4.93% ,20.28±8.51% and 35.03± 24.11% .The Dr and V20 of spinal cord were 28.02±14.09 and 4567±22.34. Conclusions: HT can reduce the high dose volume and be better protect the organ at risks ,can enhance the dose of target volume.
出处 《中国医学物理学杂志》 CSCD 2013年第6期4472-4475,4518,共5页 Chinese Journal of Medical Physics
基金 军事医学计量科研专项课题(2011-Z12-002)
关键词 胰腺癌 螺旋断层调强放疗 剂量学 Pancreas carcinoma helical tomotherapy Dosemitry
  • 相关文献

参考文献11

二级参考文献26

  • 1周颖娟,黄劭敏,邓小武.用放射性铬胶片进行调强放疗剂量验证的研究[J].中华放射肿瘤学杂志,2007,16(4):307-312. 被引量:12
  • 2胡逸民.肿瘤放射物理学[M].北京:原子能出版社,2002,10:179-211.
  • 3Ervin B.Podgorsak. Review of Radiation Oncology Physics [J]. Educational Reports Seriers, 2003:23-75.
  • 4Fuks Z,Leibel SA,Wallner KE,et al. The effect of local control on metastatic dissemination in carcinoma of the pancreas [J]. Int Jradiat Oncol Biol Phys,1997,21:537-577.
  • 5Jacob Van Dyk. The Modem Technology Radiation Oncology[J]. Medical Physics Publishing, 1999:437-481.
  • 6Poggi MM,Kroog GS,Russo A,et al.Phase I stuady of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2002,54(3):665-744.
  • 7朱庙生.影像技术与放疗设备结合[N].中国医学论坛报,2004-4:B8.
  • 8J Frank Wilson.The Tomotherapy Hi-Art System[J].MedPhy,2004,(24):1465-1476.
  • 9Jake Van Dyk,Tomas Kron,Glenn Bauman,et al.Tomotherapy:A"revolution"in radiation therapy[J].Physics inCanada,2002,58:79-86.
  • 10Craig Lewis,Tomas Kron,Jeff Chen,et al.Helical tomotherapyor IMRT to boost a'suboptimal'prostate brachytherapy implant:a feasibility study[J].Med Phys.29(2002)1941(abstract of aworks in progress paper presented at the 44st Annual Meetingof the American Association of Physicists in Medicine,Montreal,July 2002).

共引文献41

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部